Go to the list of all blogs
Alicia's Avatar
published in Blogs
Apr 28, 2026
Why Is Sportradar Group (SRAD) Stock Down -11% Today?

Why Is Sportradar Group (SRAD) Stock Down -11% Today?

Key Takeaways

  • Shares of SRAD are declining approximately 10.27% on Tuesday, April 28, 2026, falling from a prior close of $13.93 to approximately $12.50, as the compound effect of Muddy Waters' short-seller allegations, Callisto Capital's corroborating accusations, multiplying class action securities fraud lawsuits, and a Q1 2026 revenue pre-announcement at the low end of investor expectations overwhelms the modest bounce that briefly stabilized the stock on April 27.

  • The primary catalyst remains the Muddy Waters short-seller report published April 22, in which the prominent activist short-seller disclosed a short position in SRAD and alleged — based on an undercover operation conducted at ICE Barcelona — that Sportradar representatives knowingly agreed to serve illegal gambling operators, triggering a 22% single-session collapse that effectively reset the stock's investment thesis.

  • A secondary compounding catalyst is SRAD's Q1 2026 preliminary revenue guidance of €307 million to €311 million — a range that, coming in the immediate aftermath of the reputational crisis, reinforces investor concern that the illegal gambling allegations may be impacting the company's ability to retain legal-market clients and close new contracts.

  • Securities fraud class action investigations announced by law firm Glancy Prongay Wolke & Rotter LLP and litigation firm Hagens Berman are adding a legal liability overhang that institutional compliance desks are treating as a material negative, forcing portfolio-level position reductions that contribute to Monday's residual and Tuesday's renewed selling.

  • The broader macro environment Tuesday remains challenging, with risk-off sentiment continuing to limit institutional appetite for high-beta, controversy-laden technology names.

  • Traders will focus on any formal company response addressing the Muddy Waters and Callisto allegations — specifically whether management schedules an investor call and provides direct, detailed rebuttal of the illegal gambling operator servicing claims — as the single most important catalyst for near-term price stabilization.

Opening Summary

Sportradar Group AG (SRAD) is a Sankt Gallen, Switzerland-headquartered sports data and technology company that collects, processes, and distributes real-time sports data and analytics to sports betting operators, sportsbooks, media companies, leagues, and sports integrity organizations across the United States, Europe, and global markets. The company provides betting odds, live streaming technology, managed trading services, and integrity monitoring tools to clients including major global sportsbooks and broadcasting platforms, making it a critical infrastructure provider within the rapidly expanding legal sports betting ecosystem. Shares are declining approximately 10.27% on Tuesday, April 28, 2026, falling from a prior close of $13.93 to approximately $12.50, resuming the post-Muddy Waters devaluation after a partial +4.82% recovery session on April 27. The market reaction reflects the persistent uncertainty around the illegal gambling operator allegations, compounded by Q1 2026 revenue guidance at the low end of analyst expectations announced after Monday's close.

Muddy Waters Short-Seller Allegations: The Continuing Fallout

The foundational catalyst for today's renewed 10.27% decline — and the broader devaluation event that has driven SRAD from $19.69 to approximately $12.50 in less than two weeks — is the April 22 Muddy Waters short-seller report alleging that the company's sales team knowingly engaged with undercover operatives representing illegal gambling operators at the ICE Barcelona gaming conference. Muddy Waters, which conducted what it described as an undercover operation, reported that Sportradar representatives indicated a willingness to proceed with business arrangements for clients seeking to target illegal markets — a direct violation of the legal and regulatory standards that define Sportradar's entire market positioning as a trusted data partner to regulated sportsbooks and national gaming authorities. The 22% single-session crash on April 22 was not simply a reaction to a short-seller opinion; it represented institutional investors rapidly repricing the binary risk that the allegations — if substantiated — could impair SRAD's relationships with regulated sportsbook clients, its sports league data rights partnerships, and its integrity services contracts with national regulatory bodies who employ the company's own monitoring tools.

Callisto Corroboration and Class Action Investigations

A material development extending the sell-off beyond the initial Muddy Waters report is corroborating commentary from Callisto Capital, which has independently echoed the concerns about SRAD's alleged willingness to serve illegal gambling operators. When two separate short-seller research operations arrive at the same conclusion about a company's alleged conduct — particularly in a highly regulated industry where compliance failures carry license revocation risk — the combined narrative becomes significantly more difficult for management to rebut with general denials. Compounding this is the announcement of securities fraud class action investigations by Glancy Prongay Wolke & Rotter LLP and Hagens Berman, which are actively soliciting shareholders who lost money following the April 22 collapse. The litigation risk dimension introduces a legal cost and management distraction overhang that extends well beyond the immediate stock price reaction and constrains the company's ability to execute on its growth strategy while managing a parallel investor relations crisis.

Q1 2026 Revenue Guidance Adds Near-Term Pressure

While the Muddy Waters allegations dominate the investment narrative, SRAD's Q1 2026 revenue guidance range of €307 million to €311 million introduces a fundamental performance dimension that amplifies Tuesday's selling. For a company trading at a significant implied growth premium — reflected in its 35x P/E multiple — a revenue guidance range at the low end of prior investor expectations signals that the first quarter of 2026 did not deliver the acceleration required to justify the valuation. The timing of this guidance release — immediately following the Muddy Waters report and during an active class action investigation period — makes it structurally impossible for investors to evaluate the Q1 result in isolation: any revenue softness, however modest, is interpreted through the lens of reputational damage risk to the existing client base.

Market Context and Trading Activity

Volume in SRAD remains substantially above the 30-day average of approximately 2.53 million shares, confirming continued institutional repositioning rather than stabilizing price discovery. The stock's 52-week range of $11.69 to $32.22 illustrates the full scope of the devaluation — with SRAD currently trading near the lower boundary of its 52-week range at approximately $12.50, only modestly above the $11.69 low reached on April 22 at the height of the initial Muddy Waters selloff. The Nasdaq Composite remains under broad macro pressure Tuesday, providing no sector tailwind that might interrupt the company-specific devaluation process. Technically, SRAD has broken conclusively below all major moving averages, and the absence of institutional support at the $13.93 prior close — which represented only a partial one-day recovery — confirms that buyers at that level lacked conviction.

Trending AI Robots

For traders navigating short-seller-driven reputational crises, compounding legal investigations, and earnings-guidance-driven selloffs in global sports data and technology companies like SRAD today, Tickeron's Trending AI Robots page provides a curated view of the platform's strongest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers, but only those demonstrating the highest real-time performance are featured in this section. Bots span a wide range of strategy types, holding timeframes, risk profiles, performance metrics, and traded symbol universes — from mean-reversion and post-crisis stabilization systems to systematic short-biased strategies suited to companies navigating active short-seller allegations. Whether you are managing risk around multi-factor reputational and fundamental selloffs or identifying structured setups across the broader technology and gaming data sector, the Trending AI Robots page is a practical starting point for AI-assisted trading.

What Comes Next for SRAD

The near-term trajectory of SRAD is almost entirely a function of how effectively and credibly the company's management responds to the Muddy Waters and Callisto allegations — a communications and governance challenge that will require more than a brief press release denial to restore institutional confidence. Investors are watching for a formal, detailed investor presentation or conference call in which management directly addresses the specific ICE Barcelona undercover operation claims, provides documentation of its client compliance screening processes, and outlines the concrete steps being taken to investigate whether any Sportradar personnel acted outside the company's stated legal compliance standards. The company's formal Q1 2026 earnings release — expected in May 2026 — will be scrutinized not only for the €307–311 million revenue line but for any evidence of client churn or contract delays that the reputational damage may have initiated. Key risks include the possibility that the illegal gambling operator allegations are substantiated through regulatory investigation, the potential for major sportsbook and league clients to conduct compliance reviews that result in contract terminations or renegotiations, the ongoing class action litigation consuming management bandwidth and generating financial liability, the structural challenge of rebuilding institutional investor trust in a company operating in a highly regulated sector where compliance reputation is the core commercial asset, and the risk that the combined effect of the Muddy Waters report, Callisto corroboration, and class action filings has permanently impaired SRAD's ability to compete for new regulated market contracts while the legal proceedings remain unresolved.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SRAD

Contributor

Alicia's AvatarAlicia|Beginner

SRAD in -12.69% downward trend, sliding for three consecutive days on September 29, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SRAD declined for three days, in 222 of 274 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRAD as a result. In 68 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for SRAD turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 36 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

SRAD moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for SRAD entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +12.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRAD advanced for three days, in 223 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

SRAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SRAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.148) is normal, around the industry mean (51.456). P/E Ratio (219.293) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.135). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.627) is also within normal values, averaging (69.875).

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Salesforce (NYSE:CRM), Shopify Inc (NASDAQ:SHOP), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM), Autodesk (NASDAQ:ADSK).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 9.9B. The market cap for tickers in the group ranges from 39 to 244.09B. SAPGF holds the highest valuation in this group at 244.09B. The lowest valued company is STIXF at 39.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 12%. RPGL experienced the highest price growth at 180%, while WCT experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 76
Price Growth Rating: 59
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
SRAD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Industry
N/A
Address
Feldlistrasse 2
Phone
+41 715177200
Employees
4882
Web
https://www.sportradar.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.